Remidio takes India’s AI success story global at India AI Impact Summit 2026

New Delhi: Remidio Innovative Solutions, India’s leading AI-powered medical imaging company, will showcase its breakthrough eye care technology at the India AI Impact Summit 2026, demonstrating how Indian innovation is preventing blindness at scale and ready to transform global healthcare.

With 16 million people screened across 55+ countries and 1.3 million AI screenings, Remidio has proven that AI can deliver real-world health impact at population scale. In the past year, the company saved 80,000 people from blindness while achieving a 97% reduction in screening costs, from ₹2,000 to just ₹60 per screening. The company will be prominently featured across multiple high-profile locations at the summit, including the main MeitY Pavilion, the Odisha State Pavilion, and the Andhra Pradesh State Pavilion, as well as the Summit Expo.

Remidio’s presence across the MeitY Pavilion and state pavilions demonstrates the confidence that government partners have in the company’s technology. This is Indian innovation solving global problems, proven AI that’s ready to scale from India to the world.

Remidio’s AI has been deployed across five Indian states, Kerala, Pondicherry, Andhra Pradesh, Odisha, and Tamil Nadu, as well as leading healthcare institutions including AIIMS, Apollo Hospitals, LV Prasad Eye Institute, Dr. Mohan’s Diabetes Specialities Centre, and Aravind Eye Hospital.

The technology’s effectiveness has been validated in the largest real-world AI assessment ever conducted. Published in The Lancet Digital Health and tested by the NHS UK, the study evaluated eight AI systems across 200,000+ patient encounters and 1.2 million retinal images. Remidio was ranked as the most balanced AI system, demonstrating both high accuracy and real-world reliability.

Remidio is the only CDSCO and CE-approved AI system capable of detecting three major causes of blindness, diabetic retinopathy, glaucoma, and age-related macular degeneration, in a single scan. The platform is fully compliant with ABDM, HIPAA, and GDPR standards, making it deployment-ready across India’s digital health ecosystem and international markets.